Amantadine and the Risk of Dyskinesia in Patients with Early Parkinson’s Disease: An Open-Label, Pragmatic Trial
Aryun Kim, Young Eun Kim, Ji Young Yun, Han-Joon Kim, Hui-Jun Yang, Woong-Woo Lee, Chae Won Shin, Hyeyoung Park, Yu Jin Jung, Ahro Kim, Yoon Kim, Mihee Jang, Beomseok Jeon
JMD. 2018;11(2):65-71.   Published online 2018 May 30     DOI: https://doi.org/10.14802/jmd.18005
Citations to this article as recorded by Crossref logo
Neuroinflammation and blood-brain barrier disruption following traumatic brain injury: Pathophysiology and potential therapeutic targets
Suraj Sulhan, Kristopher A. Lyon, Lee A. Shapiro, Jason H. Huang
Journal of Neuroscience Research.2018;[Epub]     CrossRef
Viewpoint: Developing drugs for levodopa-induced dyskinesia in PD: Lessons learnt, what does the future hold?
Susan H. Fox, Jonathan M. Brotchie
European Journal of Neuroscience.2018;[Epub]     CrossRef